The DOI matches its Crossref record.
Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children
Abstract
OBJECTIVE: To compare the safety and efficacy of azithromycin with amoxicillin/clavulanate or erythromycin for the treatment of community-acquired pneumonia, including atypical pneumonia caused by Mycoplasma pneumoniae and Chlamydia pneumoniae. METHODS: Multicenter, parallel group, double blind trial in which patients 6 months to 16 years of age with community-acquired pneumonia were randomized 2:1 to receive either azithromycin for 5 days or conventional therapy for 10 days (amoxicillin/clavulanate if < or =5 years of age or erythromycin estolate if >5 years of age). Patients from 23 geographically diverse sites were evaluated for clinical outcomes and/or adverse events at Days 3 to 5, Days 15 to 19 and 4 to 6 weeks posttherapy. Microbiology (culture or polymerase chain reaction) was done at baseline and Days 15 to 19 for bacteria, Chlamydia pneumoniae and Mycoplasma pneumoniae. Serology for C. pneumoniae and M. pneumoniae was done at baseline and 4 to 6 weeks posttherapy. RESULTS: Of 456 patients enrolled during 17 consecutive months, 420 were evaluable. Clinical success at Study Days 15 to 19 was 94.6% in the azithromycin group and 96.2% in the comparative treatment group (P = 0.735) and at 4 to 6 weeks posttherapy 90.6 and 87.1%, respectively (P = 0.330). Evidence of infection was identified in 46% of 420 evaluable patients (1.9% bacteria, 29.5% M. pneumoniae and 15% C. pneumoniae). Microbiologic eradication was 81% for C. pneumoniae and 100% for M. pneumoniae in the azithromycin group vs. 100 and 57%, respectively, in the comparator group. Treatment-related adverse events occurred in 11.3% of the azithromycin group and 31% in the comparator group (P < 0.05). CONCLUSION: Azithromycin used once daily for 5 days produced a satisfactory therapeutic outcome similar to those of amoxicillin/clavulanate or erythromycin given three times a day for 10 days for treatment of community-acquired pneumonia. Azithromycin had significantly fewer side effects than comparator drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bradley, J. S., Byington, C. L., Shah, S. S., Alverson, B., Carter, E. R., Harrison, C., Kaplan, S. L., Mace, S. E., McCracken, G. H., Moore, M. R., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir531 · Cited by 1,919
Mycoplasma pneumoniae and Its Role as a Human Pathogen
Waites, K. B., & Talkington, D. F. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.697-728.2004 · Cited by 1,339
Harris, M., Clark, J., Coote, N., Fletcher, P., Harnden, A., McKean, M., Thomson, A., & On behalf of the British Thoracic Society Standards of Care Committee (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200598 · Cited by 1,095
Epidemiology and Clinical Characteristics of Community-Acquired Pneumonia in Hospitalized Children
Michelow, I. C., Olsen, K., Lozano, J., Rollins, N. K., Duffy, L. B., Ziegler, T., Kauppila, J., Leinonen, M., & McCracken, G. H. (2004) · Pediatrics · doi:10.1542/peds.113.4.701 · Cited by 711
Etiology of community-acquired pneumonia in 254 hospitalized children
JUVÉN, T., MERTSOLA, J., WARIS, M., LEINONEN, M., MEURMAN, O., ROIVAINEN, M., ESKOLA, J., SAIKKU, P., & RUUSKANEN, O. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200004000-00006 · Cited by 643
Metadata
- Authors
- HARRIS, J.-A. S., KOLOKATHIS, A., CAMPBELL, M., CASSELL, G. H., & HAMMERSCHLAG, M. R.
- Venue
- The Pediatric Infectious Disease Journal
- Published
- 1998-10
- Volume
- 17
- Issue
- 10
- Pages
- 865-871
- ISSN
- 0891-3668 (ISSN-L)
- OpenAlex
- W2001166659
- Cited by
- 245
- References
- 0
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. https://app.cochat.ai/papers/10.1097/00006454-199810000-00004
- The paper
- HARRIS, J.-A. S., KOLOKATHIS, A., CAMPBELL, M., CASSELL, G. H., & HAMMERSCHLAG, M. R. (1998). Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. The Pediatric Infectious Disease Journal. https://doi.org/10.1097/00006454-199810000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.